Mostrar el registro sencillo del documento
Caracterización clínica, histológica, inmunofenotípica, citogenética, molecular y de la respuesta al tratamiento en pacientes con diagnóstico de Leucemia Mieloide Aguda pediátrica de novo
dc.rights.license | Atribución-NoComercial-SinDerivadas 4.0 Internacional |
dc.contributor.advisor | Linares Ballesteros, Adriana |
dc.contributor.advisor | Yunis Londoño, Juan José |
dc.contributor.author | Niño Quiroga, Laura Isabel |
dc.date.accessioned | 2021-04-23T20:43:49Z |
dc.date.available | 2021-04-23T20:43:49Z |
dc.date.issued | 2021 |
dc.identifier.uri | https://repositorio.unal.edu.co/handle/unal/79411 |
dc.description.abstract | La leucemia mieloide aguda (LMA) es una enfermedad grave de etiología compleja y con marcada variación en la supervivencia. En pediatría este grupo representa menos del 20% de las leucemias agudas a diferencia de los adultos en quienes corresponde al tipo de leucemia más común; no obstante los niños, tienen una mayor probabilidad de supervivencia debido a diferencias en las características biológicas, de la respuesta al tratamiento y a factores del huésped tales como la edad. A pesar de los esfuerzos hay pocos estudios enfocados en LMA pediátrica especialmente en países de medianos y bajos recursos donde residen la mayoría de los niños, razón por la cual este estudio tiene como objetivo describir las características clínicas, histológicas, inmunológicas, las alteraciones citogenéticas, moleculares y la respuesta al tratamiento de los pacientes diagnosticados con LMA de novo en un centro de cáncer infantil de referencia en Colombia. Materiales y métodos: Estudio descriptivo retrospectivo de tipo cohorte de 66 pacientes diagnosticados con LMA de novo en la Fundación Hospital de la Misericordia entre septiembre de 2012 y agosto de 2020. Resultados: En 66 pacientes diagnosticados se clasificaron 8,1% en riesgo favorable, 19,6% en riesgo intermedio y 72,1% en riesgo desfavorable. Con el protocolo de tratamiento institucional, el 79,3% logró remisión completa al final de la inducción. Para este protocolo la SG y SLE para el estudio fue de 40,4% y 35,7% respectivamente |
dc.description.abstract | Introduction: Acute myeloid leukemia (AML) is a serious disease of complex etiology and with marked variation in survival. In pediatrics, this group represents less than 20% of acute leukemias, as opposed to adults, in whom it corresponds to the most common type of leukemia; however, children have a greater chance of survival due to differences in biological characteristics, response to treatment, and host factors such as age. Despite the efforts, there are few studies focused on pediatric AML, especially in low-income and middle-income countries where the majority of children reside, which is why this study aims to describe the clinical, histological, immunological characteristics, cytogenetic alterations, Molecular and response to treatment in patients diagnosed with AML de novo in a reference childhood cancer center in Colombia. Materials and methods: Retrospective descriptive cohort study of 66 patients diagnosed with AML de novo at the Hospital de la Misericordia Foundation between September 2012 and August 2020. Results: In 66 diagnosed patients, 8.1% were classified as favorable risk, 19.6% as intermediate risk, and 72.1% as unfavorable risk. With the institutional treatment protocol, 79.3% achieved complete remission at the end of induction. For this protocol, the OS and DFS for the study were 40.4% and 35.7%, respectively. |
dc.format.extent | 1 recurso en línea (73 páginas) |
dc.format.mimetype | application/pdf |
dc.language.iso | spa |
dc.publisher | Universidad Nacional de Colombia |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.subject.ddc | 610 - Medicina y salud::618 - Ginecología, obstetricia, pediatría, geriatría |
dc.title | Caracterización clínica, histológica, inmunofenotípica, citogenética, molecular y de la respuesta al tratamiento en pacientes con diagnóstico de Leucemia Mieloide Aguda pediátrica de novo |
dc.type | Trabajo de grado - Especialidad Médica |
dc.type.driver | info:eu-repo/semantics/masterThesis |
dc.type.version | info:eu-repo/semantics/acceptedVersion |
dc.publisher.program | Bogotá - Medicina - Especialidad en Oncohematología Pediátrica |
dc.contributor.educationalvalidator | García Medina Johnny Francisco |
dc.contributor.educationalvalidator | Yunis Hazbún Luz Karime |
dc.contributor.educationalvalidator | Aponte Barrios Nelson Hernando |
dc.description.degreelevel | Especialidades Médicas |
dc.description.methods | Estudio descriptivo retrospectivo de tipo cohorte de 66 pacientes diagnosticados con LMA de novo en la Fundación Hospital de la Misericordia entre septiembre de 2012 y agosto de 2020. |
dc.description.researcharea | Leucemia en niños |
dc.identifier.instname | Universidad Nacional de Colombia |
dc.identifier.reponame | Repositorio Institucional Universidad Nacional de Colombia |
dc.identifier.repourl | https://repositorio.unal.edu.co/ |
dc.publisher.faculty | Facultad de Medicina |
dc.publisher.place | Bogotá |
dc.publisher.branch | Universidad Nacional de Colombia - Sede Bogotá |
dc.relation.references | PUI, Ching-Hon (ed.). Childhood leukemias. Cambridge university press, 2012. |
dc.relation.references | Xie S, Hossain J. Survival di ff erences in childhood and young adult acute myeloid leukemia : A cross-national study using US and England data. Cancer Epidemiol. 2018;54(March):19-24. doi:10.1016/j.canep.2018.03.001 |
dc.relation.references | Susan E. Puumala, PhD, Julie A. Ross, PhD, Richard Aplenc, MD, PhD, and Logan G. Spector P. Epidemiology of Childhood Acute Myeloid Leukemia. Pediatr Blood Cancer. 2013;(60):728–733. doi:DOI 10.1002/pbc.24464 |
dc.relation.references | De Moor JS, Mariotto AB, Parry C, et al. Cancer survivors in the united states: Prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev. 2013;22(4):561-570. doi:10.1158/1055-9965.EPI-12-1356 |
dc.relation.references | Lins MM, Julia M, Mello G, Ribeiro RC, Camargo B De, Fátima M De. Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low – middle-income country. 2019. |
dc.relation.references | Vardiman JW, Arber DA, Orazi A, et al. The 2016 revision to the World Health Organization classi fi cation of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2406. doi:10.1182/blood-2016-03-643544.The |
dc.relation.references | Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374(23):2209-2221. doi:10.1056/NEJMoa1516192 |
dc.relation.references | Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children’s Oncology Group Trial AAML0531. J Clin Oncol. 2014;32(27):3021-3032. doi:10.1200/JCO.2014.55.3628 |
dc.relation.references | Creutzig U, Heuvel-eibrink MM Van Den, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents : recommendations from an international expert panel Diagnosis and management of acute myeloid leukemia in children and adolescents : recommendations from an international expert panel. 2012:3187-3205. doi:10.1182/blood-2012-03-362608 |
dc.relation.references | Upadhyay VA, Fathi AT. Induction chemotherapy in acute myeloid leukaemia: Origins and emerging directions. Curr Opin Hematol. 2018;25(2):67-74. doi:10.1097/MOH.0000000000000407 |
dc.relation.references | Costo C de alto. Situación Del Cáncer En La Población Pediatrica Atendida En El SGSSS de Colombia.; 2017. https://cuentadealtocosto.org/site/images/Libro_Situacion_Cancer_Pediatrico_2017.pdf. |
dc.relation.references | Taga T, Tomizawa D, Takahashi H, Adachi S. Acute myeloid leukemia in children: Current status and future directions. Pediatr Int. 2016;58(2):71-80. doi:10.1111/ped.12865 |
dc.relation.references | Revista Colombiana de Cancerología. 2020;24(2):72-79. |
dc.relation.references | Isabel M, Rumilla V, Ballesteros AL, et al. Pediatric Research and Child Health Signs , Symptoms and Findings in Complete Blood Cell Count at Diagnosis in Children with Acute Leukemia. 2018;1(1). |
dc.relation.references | Johnston DL, Woods WG, Alonzo TA, et al. Central nervous system disease in pediatric acute myeloid leukemia : A report from the Children ’ s Oncology Group. 2017;(January):1-9. doi:10.1002/pbc.26612 |
dc.relation.references | Jaime-pérez JC, Padilla-medina JR, Fernández LT, et al. Outcomes of Adolescents and Young Adults With Acute Myeloid Leukemia Treated in a Single Latin American Center. Clin Lymphoma, Myeloma Leuk. 2018:1-7. doi:10.1016/j.clml.2018.02.002 |
dc.relation.references | Ofran Y, Rowe JM. Introducing minimal residual disease in acute myeloid leukemia. Curr Opin Hematol. 2015;22(2):139-145. doi:10.1097/MOH.0000000000000113 |
dc.relation.references | Ossenkoppele G, Schuurhuis GJ. MRD in AML : does it already guide therapy decision-making ? :356-365. |
dc.relation.references | Loken MR, Alonzo TA, Pardo L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia : a report from Children ’ s Oncology Group. 2012;120(8):1581-1588. doi:10.1182/blood-2012-02-408336. |
dc.relation.references | Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6):543-552. doi:10.1016/S1470-2045(10)70090-5 |
dc.relation.references | Article O. Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse. 2014;(January):1-10. doi:10.1038/leu.2014.186 |
dc.relation.references | Creutzig U, Van Den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel. Blood. 2012;120(16):3167-3205. doi:10.1182/blood-2012-03-362608 |
dc.relation.references | Horan JT, Alonzo TA, Lyman GH, et al. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: The Children’s Oncology Group. J Clin Oncol. 2008;26(35):5797-5801. doi:10.1200/JCO.2007.13.5244 |
dc.relation.references | Klein K, Dors N, Tissing WJE, et al. Causes of early death and treatment-related death in newly diagnosed pediatric acute myeloid leukemia : Recent experiences of the Dutch Childhood Oncology Group. 2019;(November):1-10. doi:10.1002/pbc.28099 |
dc.relation.references | Bochennek K, Hassler A, Perner C, et al. Infectious complications in children with acute myeloid leukemia : decreased mortality in multicenter trial. 2016;(November 2015):8-11. doi:10.1038/bcj.2015.110 |
dc.relation.references | Creutzig U, Zimmermann M. Longitudinal Evaluation of Early and Late Anthracycline Cardiotoxicity in Children With AML. 2007;(July 2006):651-662. doi:10.1002/pbc |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |
dc.subject.decs | Leucemia Mieloide |
dc.subject.decs | Leukemia, Myeloid |
dc.subject.decs | Recurrencia |
dc.subject.decs | Recurrence |
dc.subject.proposal | Leucemia mieloide aguda |
dc.subject.proposal | Niños |
dc.subject.proposal | Supervivencia |
dc.subject.proposal | Tratamiento |
dc.subject.proposal | Tasa de recaída |
dc.subject.proposal | Muerte relacionada con tratamiento |
dc.subject.proposal | Leukemia, Myeloid |
dc.subject.proposal | Child |
dc.subject.proposal | Survival |
dc.subject.proposal | Treatment |
dc.subject.proposal | Treatment-related death |
dc.title.translated | Clinical, histological, immunophenotypic, cytogenetic, molecular characterization and response to treatment in patients diagnosed with de novo pediatric Acute Myeloid Leukemia |
dc.type.coar | http://purl.org/coar/resource_type/c_46ec |
dc.type.coarversion | http://purl.org/coar/version/c_ab4af688f83e57aa |
dc.type.content | Text |
dc.type.redcol | http://purl.org/redcol/resource_type/TM |
oaire.accessrights | http://purl.org/coar/access_right/c_abf2 |
Archivos en el documento
Este documento aparece en la(s) siguiente(s) colección(ones)
![Atribución-NoComercial-SinDerivadas 4.0 Internacional](/themes/Mirage2//images/creativecommons/cc-generic.png)